Metformin improves endothelial function in type 1 diabetic subjects: A pilot, placebo-controlled randomized study

Diabetes, Obesity and Metabolism

Volumn 15, Issue 5, 2013, Pages 427-431

  Pitocco, D ^a   Zaccardi, F ^a   Tarzia, P ^a   Milo, M ^a   Scavone, G ^a   Rizzo, P ^a   Pagliaccia, F ^a   Nerla, R ^a   Di Franco, A ^a   Manto, A ^a   Rocca, B ^a   Lanza, G A ^a   Crea, F ^a   Ghirlanda, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Cardiovascular disease; Diabetes complications; Macrovascular disease; Metformin; Type 1 diabetes

Indexed keywords

8 ISO PROSTAGLANDIN F2; HEMOGLOBIN A1C; METFORMIN; PLACEBO; PROSTAGLANDIN F2; UNCLASSIFIED DRUG;

ADULT; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; OXIDATIVE STRESS; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; URINE LEVEL; VASCULAR ENDOTHELIUM;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BRACHIAL ARTERY; DIABETES MELLITUS, TYPE 1; DINOPROST; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; OXIDATIVE STRESS; PILOT PROJECTS; TREATMENT OUTCOME; VASODILATION;

EID: 84876340948     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12041     Document Type: Article

References (35)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes. mellitus. N Engl J Med 1993; 329: 977-986.
2. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
3. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
4. Abdelghaffar S, Attia AM. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009; 1: CD006691.
5. Vella S, Buetow L, Royle P, Livingstone S, Colhoun MH et al. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010; 53: 809-820.
6. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One 2008; 3: e3363.
7. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003; 26: 138-143.
8. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003; 149: 323-329.
9. Khan AS, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 2006; 23: 1079-1084.
10. Gin H, Messerchmitt C, Brottier E, Aubertin J. Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients. Metabolism 1985; 34: 923-925.
11. Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002; 25: 2153-2158.
12. Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 2009; 105: 145-149.
13. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010; 31: 2854-2861(Review).
14. Zaccardi F, Pitocco D, Ghirlanda G. Glycemic risk factors of diabetic vascular complications: the role of glycemic variability. Diabetes Metab Res Rev 2009; 25: 199-207 Review.
15. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17: 2309-2315.
16. Ghiadoni L, Faita F, Salvetti M, Cordiano C, Biggi A et al. Assessment of flow-mediated dilation reproducibility: a nationwide multicenter study. J Hypertens 2012; 30: 1399-1405.
17. Nerla R, Di Monaco A, Sestito A, Lamendola P, Di Stasio E et al. Transient endothelial dysfunction following flow-mediated dilation assessment. Heart Vessels 2011; 26: 524-529.
18. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001; 323: 1123-1124.
19. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: a meta-analysis. Int J Cardiovasc Imaging 2010 Aug; 26: 631-640.
20. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120: 502-509.
21. Kitta Y, Obata JE, Nakamura T, Hirano M, Kodama Y et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009; 53: 323-330.
22. Nissen SE, Nicholls SJ, Wolski K et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
23. Dormandy JA, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
24. Seeger JP, Thijssen DH, Noordam K, Cranen ME, Hopman MT et al. Exercise training improves physical fitness and vascular function in children with type 1 diabetes. Diabetes Obes Metab 2011; 13: 382-384.
25. Fuchsjäger-Mayrl G, Pleiner J, Wiesinger GF, Sieder AE, Quittan M et al. Exercise training improves vascular endothelial function in patients with type 1 diabetes. Diabetes Care 2002; 25: 1795-1801.
26. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 2010; 33: 361-365.
27. MacKenzie KE, Wiltshire EJ, Gent R, Hirte C, Piotto L et al. Folate and vitamin B6 rapidly normalize endothelial dysfunction in children with type 1 diabetes mellitus. Pediatrics 2006; 118: 242-253.
28. Economides PA, Khaodhiar L, Caselli A, Caballero AE, Keenan H et al. The effect of vitamin E on endothelial function of micro- and macrocirculation and left ventricular function in type 1 and type 2 diabetic patients. Diabetes 2005; 54: 204-211.
29. Joyce M, Moore K, Thompson C, Fitzgerald P, Fennessy F et al. Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes. Eur J Vasc Endovasc Surg 2004; 27: 432-437.
30. Mullen MJ, Wright D, Donald AE, Thorne S, Thomson H et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36: 410-416.
31. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
32. Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009; 169: 616-625.
33. Monnier L, Mas E, Ginet C, Michel F, Villon L et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
34. Kappe C, Holst JJ, Zhang Q, Sjöholm Å. Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Biochem Biophys Res Commun 2012; 427: 91-95.
35. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 2009; 11: 966-977.